AR and prostate cancer: Notably, the upregulation of transcription factors of GR, BRN2, TBX2, and NR2F1 was found to mediate the resistance to enzalutamide in CHD1-deficient prostate cancer, since inhibition of each factor re-sensitizes CHD1 loss prostate tumors to AR inhibitor (22).